| The PROTON study: profiles of blood product transfusion recipients in the Netherlands BA Borkent‐Raven, MP Janssen, CL Van Der Poel, WP Schaasberg, ... Vox sanguinis 99 (1), 54-64, 2010 | 124 | 2010 |
| Aiming for a representative sample: Simulating random versus purposive strategies for hospital selection LR van Hoeven, MP Janssen, KCB Roes, H Koffijberg BMC medical research methodology 15 (1), 90, 2015 | 120 | 2015 |
| Demographic changes and predicting blood supply and demand in the Netherlands BA Borkent‐Raven, MP Janssen, CL Van Der Poel Transfusion 50 (11), 2455-2460, 2010 | 78 | 2010 |
| Two decades of risk factors and transfusion‐transmissible infections in Dutch blood donors E Slot, MP Janssen, T Marijt‐van der Kreek, HL Zaaijer, TJ van de Laar Transfusion 56 (1), 203-214, 2016 | 64 | 2016 |
| Cost‐effectiveness of the screening of blood donations for hepatitis E virus in the Netherlands AS Vos, MP Janssen, HL Zaaijer, BM Hogema Transfusion 57 (2), 258-266, 2017 | 49 | 2017 |
| Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project K Fischer, D Lewandowski, H Marijke Van Den Berg, MP Janssen Haemophilia 18 (3), e241-e246, 2012 | 45 | 2012 |
| Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands MP Janssen, CL Van Der Poel, E Buskens, L Bonneux, GJ Bonsel, ... Transfusion 46 (6), 956-965, 2006 | 44 | 2006 |
| Costs And Benefits Of Bacterial Culturing And Pathogen Reduction In The Netherlands MP Janssen, CL van der Poel Transfusion 45, 201A, 2005 | 44 | 2005 |
| Modeling the transmission risk of emerging infectious diseases through blood transfusion W Oei, MP Janssen, CL Poel, JE Steenbergen, S Rehmet, ... Transfusion 53 (7), 1421-1428, 2013 | 42 | 2013 |
| Cost‐effectiveness of additional blood screening tests in the Netherlands BA Borkent‐Raven, MP Janssen, CL van der Poel, GJ Bonsel, ... Transfusion 52 (3), 478-488, 2012 | 42 | 2012 |
| A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A K Fischer, ME Pouw, D Lewandowski, MP Janssen, HM van den Berg, ... Haematologica 96 (5), 738-743, 2011 | 42 | 2011 |
| Carotid stenting versus carotid endarterectomy: evidence basis and cost implications MP Janssen, GJ de Borst, WPTM Mali, LJ Kappelle, FL Moll, ... European Journal of Vascular and Endovascular Surgery 36 (3), 258-264, 2008 | 41 | 2008 |
| First results of a ferritin‐based blood donor deferral policy in the Netherlands M Vinkenoog, K van den Hurk, M van Kraaij, M van Leeuwen, ... Transfusion 60 (8), 1785-1792, 2020 | 39 | 2020 |
| Cost-effectiveness of targeted screening for hepatitis C in The Netherlands CW Helsper, BA Borkent-Raven, NJ De Wit, GA Van Essen, MJM Bonten, ... Epidemiology and infection 140 (01), 58-69, 2012 | 38 | 2012 |
| COST-EFFECTIVENESS OF TARGETED SCREENING FOR HEPATITIS C IN THE NETHERLANDS CW Helsper, BA Borkent-Raven, NJ de Wit, GA van Essen, M Bonten, ... VALUE IN HEALTH 12 (7), A429-A429, 2009 | 38 | 2009 |
| Survival after transfusion in the Netherlands BA Borkent‐Raven, MP Janssen, CL Van der Poel, WP Schaasberg, ... Vox sanguinis 100 (2), 196-203, 2011 | 36 | 2011 |
| Cost‐effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands BA Borkent‐Raven, MP Janssen, CL Van Der Poel, GA De Wit, GJ Bonsel, ... Transfusion 49 (2), 311-319, 2009 | 34 | 2009 |
| Viral safety of human plasma–derived medicinal products: Impact of regulation requirements KJ Velthove, J Over, K Abbink, MP Janssen Transfusion medicine reviews 27 (3), 179-183, 2013 | 32 | 2013 |
| Health economics and outcomes methods in risk‐based decision‐making for blood safety B Custer, MP Janssen Transfusion 55 (8), 2039-2047, 2015 | 29 | 2015 |
| The collection, testing and use of blood products in Europe in 2003 CL Van der Poel, MP Janssen Final Report, 2003 | 29* | 2003 |
